Seven New Drugs Approved In EU In First Two Months of 2018

 
• By Ian Schofield

Seven products containing a new active substance were approved in Europe in the first two months of 2018: Shire's Adynovi and Roche/Chugai's Hemlibra for hemophilia A, Roche's Ocrevus for multiple sclerosis, Kyowa Kirin's Crysvita for hypophosphatemia, AstraZeneca's Fasenra for asthma, Novo Nordisk's Ozempic for diabetes, and MSD's Prevymis for prophylaxis of cytomegalovirus infection.

Approved
Seven new drugs have been approved in the EU so far this year

More from Approvals

More from Product Reviews